Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor.
A delicate balance exists between the central dopaminergic and cholinergic neurotransmitter systems with respect to motor function. An imbalance can result in motor dysfunction as observed in Parkinson's disease patients and in patients treated with antipsychotic compounds. Cholinergic receptor antagonists can alleviate extrapyramidal symptoms in Parkinson's disease and motor side effects induced by antipsychotics. The effects of anticholinergics are mediated by muscarinic receptors of which five subtypes (M(1)-M(5)) exist. Muscarinic M(4) receptors are found at high concentrations in motor parts of the striatum, suggesting a role for muscarinic M(4) receptors in the motor side effects of antipsychotics, and in the alleviation of these side effects by anticholinergics. Here we investigated the potential role of the muscarinic M(4) receptor in catalepsy induced by antipsychotics (haloperidol and risperidone) as well as the anti-cataleptic effects of the non-selective anticholinergic drug scopolamine in fully backcrossed muscarinic M(4) receptor knockout mice. The drug-induced catalepsy was strongly attenuated, but not abolished, in M(4) knockout mice as compared to wild-type controls. Scopolamine further attenuated the cataleptic response in M(4) knockout mice, suggesting that non-M(4) muscarinic receptors also participate in the anti-cataleptic effects. In conclusion, these data indicate an important role for M(4) receptors in antipsychotic-induced motor side effects and suggest that M(4) receptors could be a target for future pharmacological treatment of antipsychotic-induced as well as idiopathic parkinsonism.
Laboratory of Neuropsychiatry, Rigshospitalet University Hospital, Copenhagen, Denmark; Psychiatric Centre Copenhagen, University Hospital Copenhagen, Denmark. a.fink-jensen@dadlnet.dk
Anders
A
Fink-Jensen
Lene S
LS
Schmidt
Ditte
D
Dencker
Christina
C
Schülein
Jürgen
J
Wess
Gitta
G
Wörtwein
David P D
DP
Woldbye
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001947:Breeding; D002375:Catalepsy / Q000139:chemically induced* / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D006220:Haloperidol / Q000009:adverse effects; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D043588:Receptor, Muscarinic M4 / Q000037:antagonists & inhibitors / Q000172:deficiency*; D018967:Risperidone / Q000009:adverse effects; D012601:Scopolamine / Q000494:pharmacology
D014150:Antipsychotic Agents; D043588:Receptor, Muscarinic M4; D012601:Scopolamine; D006220:Haloperidol; D018967:Risperidone
Neuroscience. 1992 Jul;49(2):285-96
1359451
J Neurosci. 1992 Sep;12(9):3591-600
1527598
J Clin Psychopharmacol. 2008 Apr;28(2):203-9
18344731
Neuroscience. 1990;37(2):287-94
1966822
Psychopharmacology (Berl). 1985;85(2):139-42
3925479
J Neurosci. 1994 May;14(5 Pt 2):3351-63
8182478
J Clin Psychopharmacol. 1983 Oct;3(5):288-302
6138370
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10483-8
10468635
J Neurosci. 2010 Feb 10;30(6):2396-405
20147565
Nat Rev Drug Discov. 2007 Sep;6(9):721-33
17762886
Neurochem Res. 2003 Apr;28(3-4):437-42
12675128
Eur J Pharmacol. 1981 Jan 5;69(1):107-11
6110555
Neuropsychopharmacology. 1998 Feb;18(2):63-101
9430133
Life Sci. 1993;52(5-6):441-8
8441326
Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S7-14
9690964
Trends Neurosci. 1996 May;19(5):177-81
8723200
Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73
8935801
Naunyn Schmiedebergs Arch Pharmacol. 1990 Nov;342(5):523-7
1982560
Synapse. 1997 Dec;27(4):357-66
9372558
Nature. 1976 Jun 24;261(5562):717-9
945467
Neuroscience. 2001;103(4):1017-24
11301208
Brain Res Mol Brain Res. 1997 Oct 15;50(1-2):305-13
9406947
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7050-4
2402490
Annu Rev Pharmacol Toxicol. 2004;44:423-50
14744253
Annu Rev Pharmacol Toxicol. 1990;30:633-73
2188581
Neurosci Lett. 1994 Nov 21;182(1):115-8
7891875
Trends Neurosci. 1994 Jun;17(6):228-33
7521083
Prog Brain Res. 1993;98:95-101
8248542
Cochrane Database Syst Rev. 2003;(2):CD003735
12804486
Psychopharmacology (Berl). 2011 Aug;216(3):367-78
21373792
J Pharmacol Exp Ther. 1996 May;277(2):775-83
8627558
FASEB J. 2004 Sep;18(12):1410-2
15231726
Neurosci Lett. 1990 Sep 18;117(3):248-52
2094817
Eur J Pharmacol. 2003 May 2;468(1):15-9
12729838
Psychopharmacology (Berl). 1995 Jul;120(2):128-33
7480543